CSIMarket
 



Amylyx Pharmaceuticals Inc   (AMLX)
Other Ticker:  
 
 



 

What are Amylyx Pharmaceuticals Inc's Business Segments?



Amylyx Pharmaceuticals Inc is a biopharmaceutical company that aims to develop new therapies for treating neurodegenerative diseases. The company mainly focuses on developing innovative, small-molecule drugs that can treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The companyes key segment is focused on advancing its lead product candidate, AMX0035, which is a proprietary therapy currently in Phase 3 clinical trials for the treatment of ALS.

Segments:

1) Clinical Development - This segment is responsible for the development and clinical trials of AMX0035.

2) Business Development - This segment is responsible for the company's business deals, collaborations, partnerships and acquisitions to enhance business growth.

Products and Services:

1) AMX0035 - This is the company's lead product candidate, which is a combination of two compounds working synergistically to reduce the levels of neuronal cell death and promote neuron survival. AMX0035 modulates mitochondrial permeability and is expected to confer cytoprotection to healthy neurons. This drug candidate is currently under Phase 3 Clinical Trials to study its efficacy in treating ALS.

2) AMX0075 - This drug candidate is being tested in preclinical studies, and it is also a performance-enhancing supplement. AMX0075 is a proprietary oral composition of small molecules aimed at improving cognitive functions and lowering inflammation. The company plans to test AMX0075 for its ability to treat Alzheimer's Disease and Frontotemporal Dementia in humans.

3) AMX0097 - Currently, the company's preclinical research focuses on finding a third-generation molecule that can optimize the cytoprotective functions of AMX0035. AMX0097 is an analog of AMX0035 that the company believes has superior neuroprotective properties.

4) Other Programs - The company is exploring a range of therapeutic areas apart from amyloid-related conditions, including neuroinflammation, neuromuscular diseases, and protein homeostasis.

In conclusion, Amylyx Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing innovative therapies that can address the challenges of neurodegenerative diseases. The company's current product pipeline includes AMX0035, AMX0075, and AMX0097, which are in varying stages of development. The drugs developed by the company are aimed at treating amyotrophic lateral sclerosis, Alzheimer's Disease, and Frontotemporal Dementia, among other neurodegenerative diseases.
   

Amylyx Pharmaceuticals Inc Tax Rate Companies within the Major Pharmaceutical Preparations Industry


Business Segments Q3
Revenues
(in millions $)
Q3
Income
(in millions $)
(Sep 30 2023)
%
(Profit Margin)
Total 102.69 20.89 20.35 %

Growth rates by Segment Q3
Y/Y Revenue
%
(Sep 30 2023)
Q/Q Revenue
%
Q3
Y/Y Income
%
(Sep 30 2023)
Q/Q Income
%
Total 29666.09 % 4.56 % - -5.35 %

To get more information on Amylyx Pharmaceuticals Inc's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com